Background-␤-Adrenergic receptor blockade is one of the most effective treatments for heart failure, a leading cause of mortality worldwide. The use of ␤-adrenergic receptor blockers in patients with heart failure is counterintuitive, however, because they are known to decrease contractility in normal hearts. The ryanodine receptor (RyR2) on cardiac sarcoplasmic reticulum is the key calcium release channel required for excitation-contraction coupling. In failing hearts, the stoichiometry and function of the RyR2 macromolecular complex is altered. Decreased levels of phosphatases (PP1 and PP2A) and hyperphosphorylation by protein kinase A result in dissociation of the regulatory protein FKBP12.6 and channels with increased open probability. Methods and Results-Here, we show that systemic oral administration of a ␤-adrenergic receptor blocker reverses protein kinase A hyperphosphorylation of RyR2, restores the stoichiometry of the RyR2 macromolecular complex, and normalizes single-channel function in a canine model of heart failure. Conclusions-These results may, in part, explain the improved cardiac function observed in heart failure patients treated with ␤-adrenergic receptor blockers. 
C linical trials have shown that ␤-adrenergic receptor blocker therapy results in a 20% to 66% reduction in mortality at 12 months in patients with heart failure (HF). [1] [2] [3] It is not intuitively obvious, however, how ␤-adrenergic receptor blockers can improve cardiac function in failing hearts, because they are known to decrease contractility in normal hearts. 4 -6 HF is a complex disease 7 that is characterized by a hyperadrenergic state. 8 However, ␤ 1 -adrenergic receptors are downregulated and uncoupled from G proteins in failing hearts. 9, 10 Nevertheless, we recently showed that ryanodine receptor (RyR2) is protein kinase A (PKA)-hyperphosphorylated in HF, 11 indicating that the net effect of ␤-adrenergic signaling is upregulated in HF with respect to RyR2 as a substrate for PKA phosphorylation. It is likely that the PKA hyperphosphorylation of RyR2 is a maladaptive response, 12 because it results in the depletion of the regulatory subunit FKBP12. 6, 11, 13 yielding channels that are pathologically sensitive to Ca 2ϩ -induced Ca 2ϩ release from the sarcoplasmic reticulum (SR). 11 RyR2 is a macromolecular complex that includes FKBP12.6 as well as PKA and 2 phosphatases (PP1 and PP2A) that are bound to the cytoplasmic domain of the channel via targeting proteins. 11, 14 In failing hearts, the RyR2 macromolecular complex undergoes remodeling characterized by a reduction in the amounts of PP1, PP2A, and FKBP12.6 that are bound to the cytoplasmic domain of the channel. 11 In the present study, we used a well-characterized canine model of pacing-induced HF to show that ␤-adrenergic receptor blockade both restores the normal stoichiometry of the RyR2 macromolecular complex and normalizes the function of the channel.
Methods

HF Model
Seventeen dogs weighing 28 to 30 kg were used for the study. A rapid cardiac pacing regimen that results in severe HF was used as described previously. 15 Animals were assigned to 1 of 4 groups: (1) normal without heart instrumentation (nϭ6), (2) HF (nϭ10), (3) HF treated with metoprolol (nϭ6), and (4) normal without heart instrumentation plus metoprolol (nϭ2). In groups 2 and 3, after baseline measurements had been obtained, rapid left ventricular (LV) pacing was initiated at 210 bpm for 3 weeks, followed by an additional week of pacing at 240 bpm with an external pacemaker (EV4543, Pace Medical, Inc). Metoprolol (25 mg PO BID, Mylan Pharmaceuticals Inc) was begun 2 weeks after initiation of pacing and continued for 2 weeks. Metoprolol was begun 2 weeks after baseline measurement for the control dogs with heart instrumentation. Hemodynamic assessment was performed at baseline and at 2, 3, and 4 weeks. Hemodynamic measurements were performed Ն40 minutes after the pacemaker was turned off. Baseline LV change in pressure over time (dP/dt max , mm Hg/s) was 3441Ϯ117 (nϭ24) and fell to 1730Ϯ304 (nϭ10, PϽ0.01) in animals subjected to rapid LV pacing, consistent with the development of HF. Because rapid LV pacing was continued throughout the metoprolol treatment period, this model was not designed to assess whether ␤ 1 -adrenergic receptor blockade restores normal hemodynamic function in failing hearts. It has previously been demonstrated, however, that ␤ 1 -adrenergic receptor blockade, including therapy with metoprolol, improves LV function in HF in both humans and dogs 16, 17 and improves survival. 2 
Ryanodine Receptor Macromolecular Complex
SR membranes were prepared from canine ventricular tissue as described previously. 11, 18 Protein concentration was measured by Bradford assay. SR samples were stored at Ϫ80°C until use. . Samples were size-fractionated on 6% SDS-PAGE, and RyR2 radioactivity was quantified with a Molecular Dynamics PhosphorImager and ImageQuant software (Amersham Pharmacia Biotech). Nonspecific phosphorylation (not inhibited by PKA inhibitor) was subtracted, and the resulting value was divided by the amount of RyR2 protein (determined by immunoblotting and densitometry) and expressed as the inverse of the specific PKA-dependent [␥-32 P]ATP signal. Cardiac homogenates were immunoprecipitated with anti-RyR antibody, and samples were size-fractionated with SDS-PAGE and immunoblotted as previously described. 11 Primary antibodies used were anti-PKA catalytic subunit 1:1000, anti-PP1 1:1000, anti-RII 1:1000, and anti-PP2A 1:1000 from Transduction Laboratories; anti-FKBP 1:1000 19 ; and anti-RyR (5029, 1:3000). 19 Data shown represent results from 3 or more separate experiments.
␤-Adrenergic receptor binding studies were performed as previously described 20 : adrenergic receptor density and affinity were reduced in the failing hearts (normal hearts: B max ϭ36.5Ϯ0.9 fmol/ mg, K d ϭ4.3Ϯ0.3 nmol/L versus failing hearts: B max ϭ29.7Ϯ0.3 fmol/mg, K d ϭ10.0Ϯ0.8 nmol/L, nϭ6, PϽ0.01), and both were restored to normal with metoprolol (B max ϭ34.9Ϯ2.1 fmol/mg, K d ϭ6.2Ϯ1.7 nmol/L, nϭ6, PϽ0.01 compared with failing hearts, PϭNS compared with normal hearts).
Single-Channel Recordings
Single-channel recordings of RyR2 were performed and analyzed under voltage-clamp conditions as described previously. 11 21 At the conclusion of each experiment, ryanodine or ruthenium red was applied to confirm the identity of channels as RyR2. Results are presented as meanϮSD; Student's t test or ANOVA (where indicated) was used for statistical analyses.
Results
HF was induced by rapid LV pacing and verified by hemodynamic measurements showing a significant increase in LV end-diastolic pressure from 5.4Ϯ2.5 to 23.1Ϯ4.8 mm Hg (nϭ10, PϽ0.01). After the establishment of HF, animals were treated with the ␤ 1 -adrenergic receptor blocker metoprolol (25 mg PO BID), a dose that is comparable to or less than that used in patients 16 with HF.
As we previously reported, 11 RyR2 was PKA-hyperphosphorylated in failing hearts (Figure 1 ). PKA phosphorylation of immunoprecipitated RyR2 was assessed with backphosphorylation as previously described. 11 Metoprolol treatment reversed the PKA hyperphosphorylation of RyR2 in failing hearts, returning the channel phosphorylation to the levels seen in normal nonfailing hearts (Figure 1) . Because there is a single site on each RyR2 molecule (serine 2809) that is PKA-phosphorylated in vivo, there are 4 per tetrameric channel. 11 The stoichiometry of PKA backphosphorylation of RyR2, determined as previously described, 11 was 3.18Ϯ0.02 moles of phosphate transferred per mole of channel from normal hearts (nϭ6), compared with 0.72Ϯ0.13 moles of phosphate transferred per mole of channel from failing hearts (nϭ10, PϽ0.01 compared with normal hearts by ANOVA) and 2.94Ϯ0.15 moles of phosphate transferred per mole of channel (nϭ6, PϭNS compared with normal hearts by ANOVA) from failing hearts in animals treated with metoprolol. These data indicate that in failing hearts, Ϸ3 of 4 PKA sites on the tetrameric RyR2 were PKA-phosphorylated in vivo, whereas only 1 of these sites was PKA-phosphorylated in RyR2 from normal hearts and in failing hearts in animals treated with metoprolol. ␤ 1 -Adrenergic receptor blockade of normal animals had no effect on RyR2 PKA phosphorylation.
To determine the effects of pacing-induced HF and ␤-adrenergic receptor blocker treatment on the RyR2 macromolecular complex, RyR2 was immunoprecipitated from cardiac homogenates, and the levels of components of the macromolecular complex were determined by immunoblotting as previously described 11 ( Figure 2) . As previously reported, 11 no significant differences in the levels of PKA ( Figure 2B ) and RII (PKA regulatory subunit) ( Figure 2C ) were associated with RyR2 in the failing versus normal hearts, whereas the amount of the phosphatases PP2A ( Figure  2D ) and PP1 ( Figure 2E ) in the RyR2 macromolecular complex were significantly reduced (PϽ0.01 by ANOVA) in the failing hearts compared with normal controls (Figure 2) . Treatment with metoprolol restored PP1 and PP2A levels in the RyR2 macromolecular complex in failing hearts back to those seen in normal hearts (Figure 2 ). Cellular PP1 levels are increased in the failing heart 22 ; thus, the observed decreased association of PP1 with RyR2 is probably not explained by a generalized decrease in phosphatase levels and is due to a specific reduction in the targeting of PP1 to RyR2. Targeting of PP1 and PP2A to the RyR2 macromolecular complex was restored to normal levels by ␤-adrenergic receptor blockade ( Figure 2D and 2E) .
We have previously shown that PKA hyperphosphorylation of RyR2 in failing hearts dissociates the channel regulatory protein FKBP12.6 from RyR2, resulting in defective channel function characterized by increased open probability (P o ) and increased gating frequency (f o ). 11 A significant (PϽ0.01 by ANOVA) decrease in the amount of PP1, PP2A, and FKBP12.6 was associated with RyR2 in failing hearts compared with normal hearts (Figure 2A through 2F) . Metoprolol treatment of HF animals restored the level of FKBP12.6 bound to RyR2 to normal ( Figure 2F) ; there is no change in the total amount of FKBP12.6 in failing versus normal hearts. 11 Like FKBP12, which stabilizes skeletal muscle RyR1 function 19, 23, 24 and is required for coupled gating between individual channels, 25 FKBP12.6 plays a similar role in the RyR2 macromolecular complex. 11, 18, 26 To determine whether the ␤-adrenergic blockade-induced normalization of PKA phosphorylation of RyR2 and restoration of the stoichiometry of the macromolecular complex was associated with normalization of channel function, we examined the single-channel properties of RyR2 in planar lipid bilayers as previously described. 11 One hundred fifty-three RyR2 channels were studied, including 55 channels from 4 nonfailing canine hearts ( Figure 3A ), 55 channels from 5 failing canine hearts ( Figure 3B ), and 43 channels from 4 failing hearts from animals treated with metoprolol ( Figure  3C ). Compared with RyR2 from normal hearts, RyR2 channels from failing hearts exhibited significantly increased P o and/or f o (Table and Figure 3A , compared with Figure 3B ). Both increased P o and increased f o are seen when FKBP12.6 is removed from RyR2. 11, 18 Compared with channels from normal hearts, in which 0 of 55 channels exhibited increased P o or f o , 93% (51/55) of the RyR2 channels from failing hearts were abnormal, exhibiting increased P o and/or f o (Table) . In contrast, only 12% of the RyR2 channels (5/43, PϽ0.01) from failing hearts from animals treated with metoprolol were abnormal (Table) . Although 93% of the RyR2 channels from failing hearts exhibited abnormal function in planar lipid bilayers, as previously reported, 11 the single-channel properties were heterogeneous (Table and Figure 3B ). This heterogeneity may reflect the fact that each individual channel may have anywhere from 0 to 4 of the 4 possible serines phosphorylated and may have anywhere from 0 to 4 molecules of FKBP12.6 bound to the channel. The single-channel properties of RyR2 from failing hearts would be expected to be heterogeneous, with only a subset of channels exhibiting the most severe defects. If all of the RyR2 channels from failing hearts had increased P o at low cis (cytosolic Ca 2ϩ ), this would be incompatible with life. To assess the heterogeneous function of RyR2 from failing hearts, the channels were segregated into 3 clearly distinguishable functional groups (Table) . Group A includes channels with normal P o and f o , Group B includes channels with normal P o and increased f o , and Group C includes channels with increased P o and f o . Thus, group C includes channels with the most severe functional defects. There were no channels from normal hearts in groups B or C, whereas 93% of the channels from failing hearts were in groups B or C, with 45% in group C. Of the channels from HF treated with ␤-blockers, 12% were in groups B or C but only 6% were in group C. This heteroge- neity in the function of RyR2 channels from failing hearts is consistent with our previous observation that Ϸ70% of the channels exhibited abnormal single-channel properties, including 56% that exhibited some increase in P o at low cis (cytosolic, 150 nmol/L) Ca 2ϩ and 15% that exhibited a large increase in P o at 50 nmol/L cis (cytosolic) Ca 2ϩ . 11
Discussion
Taken together, these data indicate that systemic ␤-adrenergic blockade can reverse the defects in the structure and function of RyR2 observed in failing hearts. 11 Regulation of Ca 2ϩ homeostasis in cardiomyocytes is a complex process that requires the integrated function of multiple Ca 2ϩ -handling Figure 3 . ␤-Adrenergic receptor blockade normalizes RyR2 function in failing hearts. RyR2 channels from (A) normal canine heart, (B) pacing-induced failing canine heart, and (C) failing hearts treated with metoprolol were studied in planar lipid bilayers. Recordings were at 0 mV, and closed state of channels is indicated (C 17,30,36 -39 We have proposed that hyperphosphorylated RyR2 depleted of FKBP12.6 could contribute to a reduction in SR Ca 2ϩ content and uncoupling of RyR2. 26 The chronic alterations in RyR2 function could contribute to a reduction in excitation-contraction coupling gain and decreased Ca 2ϩ transients in failing hearts and possibly produce diastolic Ca 2ϩ release that can trigger delayed afterdepolarizations 40 and initiate fatal ventricular cardiac arrhythmias (sudden cardiac death). 11, 12 In agreement with these possibilities, recent studies have shown either a reduction in SR Ca 2ϩ content, 41 decreased Ca 2ϩ transients, 42 or decreased excitation-contraction coupling gain 43 in cardiomyocytes from failing hearts as well as reduced levels of FKBP12.6 in the RyR2 macromolecular complex. 44 Systemic ␤-adrenergic receptor blockade therapy has multiple effects on a wide range of signaling molecules both in the heart and in other tissues. The present study focuses on one of these pathways and demonstrates normalization of RyR2 structure and function in failing hearts treated with ␤-adrenergic receptor blockade. RyR2 is one of the first molecular targets identified for ␤-adrenergic receptor blockade therapy outside of the ␤-adrenergic receptor signaling pathway. The restoration of normal RyR2 structure and function contributes to a mechanistic understanding that may in part explain some of the beneficial effects of ␤-adrenergic receptor blockade observed in HF.
